TLX:NASDAQTelix Pharmaceuticals Limited Analysis
Data as of 2026-08-31 - not real-time
$11.08
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Telix Pharmaceuticals Limited trades at $11.08, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has gained 5.4% over the past 30 days. RSI sits at 47.1, which reads as neutral, and MACD momentum is bearish. Price has been bracketed by support at $10.15 and resistance at $12.48.
On valuation the read is overvalued — earnings multiple of 110.8 versus a 30.4 sector average, above the peer group. The average analyst target implies 91.4% above today's level. Revenue is growing at 22.3% on a 3.8% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 52.9%, a beta of 1.04 and a maximum drawdown of 41.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
On valuation the read is overvalued — earnings multiple of 110.8 versus a 30.4 sector average, above the peer group. The average analyst target implies 91.4% above today's level. Revenue is growing at 22.3% on a 3.8% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 52.9%, a beta of 1.04 and a maximum drawdown of 41.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top Market Events
Radiopharmaceutical manufacturer Telix Pharmaceuticals reported 477 million dollars in half-year group revenue on 20...media 1165807 MELBOURNE, Australia and INDIANAPOLIS, Aug.MELBOURNE, Australia and INDIANAPOLIS, Aug.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 9.40
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 110.8 versus sector average of 30.4
- Trading above the 200-day average of 9.40
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 110.8 versus sector average of 30.4
- Analyst targets imply +91.4% versus the current price
- Revenue growth of +22.3%
Key Metrics & Analysis
Financial Health
Revenue Growth22.30%
Profit Margin3.76%
P/E Ratio110.8
ROE7.36%
ROA2.71%
Debt/Equity118.90
P/B Ratio9.0
Op. Cash Flow$-12006000
Free Cash Flow$-62596000
Industry P/E30.4
Technical Analysis
TrendBullish
RSI47.1
Support$10.15
Resistance$12.48
MA 20$11.53
MA 50$11.11
MA 200$9.40
MACDBearish
VolumeIncreasing
Fear & Greed Index94.32
Valuation
Target Price$21.20
Upside/Downside91.37%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.04
Volatility52.93%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.